^
Association details:
Biomarker:KIT mutation
Cancer:Mucosal Melanoma
Drug:temozolomide (DNA synthesis inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Continuous infusion of Endostar combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: A real-world cohort study

Published date:
05/19/2021
Excerpt:
Patients received dacarbazine plus cisplatin or temozolomide plus cisplatin regimens...An objective response was observed in 12 (30.0%) of the 40 evaluable patients, and disease control was achieved in 31 (77.5%) patients....BRAF/KIT/RAS mutation (p = 0.028, HR 0.24, 95% CI: 0.07-0.86) were independently correlated with prolonged OS....Continuous Endostar infusion in combination with chemotherapy was effective and safe for the treatment of advanced or recurrent mucosal melanoma.
Secondary therapy:
cisplatin + recombinant human endostatin
DOI:
10.1200/JCO.2021.39.15_suppl.e21517